Aug 09, 2023 / 05:00PM GMT
John Newman - Canaccord Genuity Group Inc. - Analyst
Everyone for joining us here at the 43rd Annual Canaccord Genuity Growth Conference in Boston. I'm John Newman, I'm one of the senior biotech analysts here at the firm. So we're very excited to have Adicet with us today.
And joining us today is the CEO, Chen Schor. Chen, welcome. So Chen, I wondered if you could start off maybe just by giving us a very brief background on Adicet for those that don't know the company well. You've got an off-the-shelf CAR T approach, different target than others. Wondering if you could describe a bit for us.
Chen Schor - Adicet Bio, Inc. - President & CEO
Sure, absolutely. But first of all, John, thank you for inviting us. Adicet was founded in 2015 looking to develop a cell therapy that can result in meaningful benefits to patients, both in hematologic tumors and in solid tumors. And we're focusing on a specific type of -- cell type called the gamma-delta 1 T-cells.
Perhaps it might be helpful to understand the gamma-delta 1 asset class versus, for
Adicet Bio Inc at Canaccord Genuity Growth Conference Transcript
Aug 09, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers